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Ovarian cancer is the second most common and the most lethal
gynaecologic malignancy (Boring et al, 1994; England et al, 1995)
with an average 5-year survival rate of 39% (Kristensen and
Trope, 1997). The low survival rate is mainly due to the lack of
sensitive tests for detection of early stage disease, which is often
asymptomatic. At the time of diagnosis, about two thirds of the
patients manifest advanced stage disease. Therefore, identification
of reliable diagnostic biomarkers would greatly improve the out-
comes of ovarian cancer by enabling early detection. Furthermore,
identification of prognostic and predictive biomarkers would aid
in the optimal management of these patients. Genes which display
altered expression in cancer cells are generally considered as
candidate tumour biomarkers and should be evaluated for possible
correlation between their expression and patient prognosis. In this
endeavour, serine proteases have received much attention in recent
years. 
Serine proteases serve several functions during tumour progres-
sion, including stimulating cellular growth, angiogenesis as well
as degradation of extracellular matrix (Tryggvason et al, 1987;
Duffy, 1991; Liotta et al, 1991). In particular, the last function is
thought to be critical in conferring the invasiveness and metastatic
potential of cancer cells (Hanahan and Weinberg, 2000). Indeed,
this biological role of serine proteases seems to accord well with
clinical reports which show that aberrant expression of serine
proteases such as the plasminogen activator correlate positively
with the invasiveness and metastasis, hence poor prognosis in
different malignancies (Monsky et al, 1991; Powell et al, 1993;
Herszenyi et al, 1999; Kuhn et al, 1999; Herszenyi et al, 2000). 
The kallikrein gene family comprises at least 14 structurally
related genes around chromosome 19q13.2-q13.4. (Yousef et al,
1999; Diamandis et al, 2000). Kallikrein gene 5 (KLK5; also
known as KLK-L2 or human stratum corneum tryptic enzyme
[HSCTE]) is one of the newly identified members of this gene
family (Yousef and Diamandis, 1999). Structurally, KLK5 is likely
to be synthesized as a preproenzyme that contains an N-terminal
signal peptide (prezymogen) followed by an activation peptide and
the enzymatic domain. In addition, sequence homology analysis
relates KLK5 most closely with the enamel matrix serine
proteinase 1 (EMSP1) while sharing a high degree of homology
with other kallikreins, including PSA. Many new reports have
shown that various members of the kallikrein gene family are
differentially regulated in cancer. Specifically, the stratum
corneum chymotryptic enzyme (KLK7), neuropsin (KLK8) and
zyme (KLK6) have been shown to be overexpressed in ovarian
tumours (Anisowicz et al, 1996; Tanimoto et al, 1999; Underwood
et al, 1999) while the normal epithelial cell-specific 1 gene (NES1;
KLK10) is down-regulated (Liu et al, 1996; Goyal et al, 1998). 
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doi: 10.1054/ bjoc.2000.1649, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn the present study, we have evaluated KLK5 mRNA expres-
sion in relation to patient survival and other clinicopathologic vari-
ables in epithelial ovarian carcinoma. Our results demonstrate that
KLK5 is an independent prognostic marker of poor prognosis in a
subset of patients with grade I/II tumours.
MATERIALS AND METHODS 
Ovarian cancer specimens and patients 
142 consecutive patients with epithelial ovarian carcinoma were
included in this study, with ages ranging from 25 to 80 with a
median of 59 years. Patients underwent surgery and treatment for
primary ovarian carcinoma at the Department of Obstetrics and
Gynecology, Gynecologic Oncology Unit, University of Turin,
Turin, Italy between July, 1991 and April, 1999. Follow-up informa-
tion (median follow-up period 48 months) was available for 138
patients, among whom 83 (60%) have relapsed and 55 (40%) died.
Of the 142 ovarian adenocarcinomas, for which histological diag-
nosis was available, 64 (45%) were serous papillary, 26 (18%)
endometrioid, 22 (16%) undifferentiated, 12 (8%) clear cell, 11
(8%) mucinous, 6 (4%) Mullerian and 1 (1%) was unclassified.
Due to the relatively small sample size, the clear cell, mucinous
and Mullerian types were combined into one category termed
‘others’. Classification of histological types followed the World
Health Organization criteria (Serov and Sorbin, 1973). All patients
were staged according to the International Federation of
Gynecology and Obstetrics staging system (Pettersson, 1994).
Grading information was available for 141 patients, 10 (7%) had
low potential malignancies (LPM), 17 (12%) had grade 1, 24
(17%) had grade 2 and 90 (64%) had grade 3 ovarian carcinoma.
Grading was established for each ovarian tumour according to the
criteria of Day et al. (1975). Debulked tumour specimens were
stored in liquid nitrogen immediately after frozen section and
shipped at 280˚C. All patients were treated with cisplatin-based
chemotherapy regimens based on a platinum compound, alone or
in association with other drugs; grade 1 and stage I patients
received no further treatment. Investigations were performed in
accordance with the Helsinki declaration and were approved by
the Institute of Obstetrics and Gynecology, Turin, Italy. 
Preparation of total RNA 
50–100 mg of tumour tissue was pulverized on dry ice, followed
by total RNA extraction using the TRIzol® method (Gibco BRL,
Gaithersburg, MD). Following measurement of total RNA concen-
tration by spectrophotometry, 4 mg of total RNA from each tissue
was used to carry out first strand cDNA synthesis using the
SuperScript™ Preamplification System, as prescribed by the
manufacturer (Gibco BRL). To test the success of cDNA
synthesis, 1 ml of the reverse transcription product was amplified
using PCR with primers specific for actin. Product was visualized
on a 2% agarose gel stained with ethidium bromide. 
Assessment of KLK5 expression 
One  ml of the first strand cDNA product was amplified using
HotStar Taq DNA polymerase in PCR reactions as prescribed by
the manufacturer (Qiagen Inc, Mississauga, Ontario, Canada).
Primers used in this reaction (5¢CAA GAC CCC CCT GGA TGT
GG3¢ and 5¢CCGAGACGGACTCTGAAA ACT TTCTTCC3¢)
were specific for KLK5. PCR reactions were carried out in an
Eppendorf thermocycler (enzyme activation at 95˚C for 15 min;
40 cycles of denaturation at 94˚C for 30 s, annealing at 65˚C
for 1 min, extension at 72˚C for 30 s; final extension at 72˚C for
10 min) and the 340 bp KLK5 PCR product was visualized with
ethidium bromide on 2% agarose gels. Gels were photographed
under UV light with Speedlight Gel Documentation System
(Lightools Research, Encinitas, CA) using 20 ´ magnification.
Images were scored by 2 independent observers for presence
(positive) or absence (negative) of a KLK5 PCR-generated band.
Each PCR reaction was performed twice to evaluate repro-
ducibility of data. 
Statistical analysis 
Associations between clinicopathological parameters such as
stage, grade, histotype and residual tumour, and KLK5 expression
were analysed by the chi-square test or the Fisher’s Exact Test
when appropriate. 
For survival analysis, two different end points – cancer relapse
(either local recurrence or distant metastasis) and death – were
used to calculate progression free and overall survival, respect-
ively. Progression-free survival was defined as the time interval
between the date of surgery and the date of identification of recur-
rent or metastatic disease. Overall survival was defined as the time
interval between the date of surgery and the date of death. 
The Cox univariate and multivariate proportional hazard regres-
sion model (Cox, 1972) was used to evaluate the hazard ratio (rel-
ative risk of relapse or death in the KLK5-positive group). In the
multivariate analysis, the models were adjusted for KLK5 expres-
sion, clinical stage, histologic grade, residual tumour and age. 
Kaplan–Meier survival curves (Kaplan and Meier, 1958) were
constructed for KLK5-positive and KLK5-negative patients. 
For further analysis, patients were divided into 2 groups either by
the tumour grade (grade I–II vs. grade III) or by the success of
debulking (optimal vs. suboptimal debulking group). In each
category, survival rates (disease-free survival and overall survival)
were compared between KLK5-positive and KLK5-negative
groups. The differences between the survival curves between
groups were tested for statistical significance by the log rank test
(Mantel, 1966). 
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Figure 1 Expression of the KLK5 gene as determined by RT-PCR. Total
RNA was extracted from normal (n = 10, top) and cancerous ovarian tissues
(n = 142, a representative blot shown in bottom), and used for RT-PCR. Actin
was used as a control gene RESULTS 
Relationship between KLK5 expression and other
parameters 
From the 142 patients included in this study, 58 (41%) were
positive for KLK5 expression in their ovarian tissue. In 10 normal
ovarian tissues, the level of KLK5 was undetectable or low (Figure
1). Table 1 depicts the distribution of KLK5 expression (positive
or negative) in ovarian tumour tissues in relation to clinical stage,
histological grade, histotype, size of residual tumour, menopausal
status and chemotherapy response. A significantly higher
percentage of patients with advanced stage (P = 0.027) and higher
grade (P = 0.006) tumour had detectable KLK5 expression. On
the other hand, comparison of KLK5 expression in relation to
response to chemotherapy revealed that KLK5 positivity was
associated with lack of response (P = 0.029). No significant asso-
ciations were found between KLK5 expression and different histo-
types,  residual tumour size, debulking success or menopausal
status. 
Survival analysis 
Out of the 142 patients included in this study, follow-up informa-
tion was available for 138 of them with a median follow-up period
of 48 months. 83 patients suffered a relapse and 55 of them died.
Table 2 presents the association between cancer relapse or death,
and various prognostic parameters. Data from the univariate
analysis suggest that patients positive for KLK5 expression have
1.68- and 1.83-fold greater risk of relapse (P = 0.018) and death 
(P = 0.022), respectively. As expected, disease stage, grading and
residual tumour were found to be strongly associated with
increased risks of relapse and death (P < 0.001). Kaplan–Meier
survival curves (Figure 2) demonstrate that KLK5-negative
patients live longer and relapse less frequently. On the other hand,
when Cox analysis was adjusted by stage of disease, grading,
residual tumour, histologic type and age in the multivariate
model, the prognostic value of KLK5 was no longer statistically
significant. As expected, disease stage and residual tumour size
were found to be the strongest independent indicators of poor
prognosis. 
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Table 1 Relationship between KLK5 status and other variables in primary ovarian cancer 
No. of patients (%) 
Variable Patients KLK5 negative KLK5 positive  P value 
Stage 
I 28 22 (78.6) 6 (21.4)
II 10 7 (70.0) 3 (30.0) 0.027a
III 92 50 (54.3) 42 (45.7)
IV 10 3 (30.0) 7 (70.0)
X2
Grade 
GB (Borderline) 10 9 (90.1) 1 (10.0)
G1 17 15 (88.2) 2 (11.8) 0.006a
G2 24 13 (54.2) 11 (45.8)
G3 90 46 (51.1) 44 (48.9)
X1
Histotype 
Serous 64 36 (56.3) 28 (43.8)
Endometrioid 26 17 (65.4) 9 (34.6) 0.789a
Undifferentiated 22 12 (54.5) 10 (45.5)
Others 30 19 (63.3) 11 (36.7)
Residual tumor (cm) 
0 57 39 (68.4) 18 (31.6)
1–2 27 12 (44.4) 15 (55.6) 0.103a
>2 56 32 (57.1) 24 (42.9)
X2
Debulking successc
OD 69 46 (66.7) 23 (33.3) 0.088b
SO 71 37 (52.1) 34 (47.9)
X2
Menopause 
Pre/peri 44 22 (50.0) 22 (50.0) 0.145b
Post 98 62 (63.3) 36 (36.7)
Response to CTXd
NC/PD 16 5 (31.3) 11 (68.8) 0.029b
CR/PR 121 75 (62.0) 46 (38.0)
NE 5
ac2 test; bFisher’s Exact Test; cOD; optimal debulking (0–1 cm), SO; suboptimal debulking (>1 cm); dCTX;
chemotherapy, NC; no change, PD; progressive disease, CR; complete response, PR; partial response, 
NE; not evaluated; X; status unknown. Survival analysis in patients stratified by the tumour
stage, grade or success of debulking 
We further examined the associations between the presence of
KLK5 and cancer relapse or death in subgroups of patients who
were categorized based on either stage (stage I and II vs III and IV)
histologic grade (grade I/II vs. grade III) or debulking success
(optimal debulking vs. suboptimal debulking). Among patients
with grade I/II tumours, KLK5 positivity was associated with
approximately 3–4-fold greater risk of relapse in both univariate
(P = 0.006) and multivariate analysis (P = 0.018) (Table 3).
Similarly, there was a tendency for increased risk of death in the
KLK5-positive group, but this did not reach statistical significance
in the Cox regression model (P = 0.055). On the other hand,
Kaplan–Meier curves (Figure 3) demonstrate that among patients
with grade I/II tumours, KLK5-negative patients show signific-
antly higher probability of both relapse-free survival (P = 0.003)
and overall survival (P = 0.043). Conversely, as shown in Table 3
and Figure 4, patients with grade III tumours were found to be
equally likely to suffer a relapse or die, regardless of their KLK5
expression status, with comparable hazard ratios between KLK5-
positive and -negative groups. 
Table 4 presents relative risks of relapse and death of KLK-
positive or -negative patients, in relation to their debulking success.
Among patients showing optimal debulking, presence of KLK5
was associated with an approximately 3-fold increase in the risk of
relapse in both univariate (P = 0.008) and multivariate analysis 
(P = 0.049) while KLK5 expression status did not show a signifi-
cant relation with the risk of death. This finding was consistent
with the results of the Kaplan–Meier survival analysis (Figure 5).
In the group of patients with suboptimal debulking, KLK5 expres-
sion was associated with an increased (two-fold) risk of death in
both univariate (P = 0.023) and multivariate analysis (P = 0.006)
while no significant association was found between the KLK5
expression and the risk of relapse (Table 4). Kaplan–Meier
survival curves produced similar data (Figure 6). 
No statistically significant association was found between
KLK5 expression and risk of relapse or death in the group of
patients with stage I and II vs III and IV, in both univariate and
multivariate analysis. Kaplan–Meier survival curves produced
similar results (data not shown). 
DISCUSSION 
Protease-mediated degradation of extracellular matrix promotes
tumour invasiveness and metastasis. The present study demon-
strates that KLK5 expression is low in normal ovaries but it is
significantly higher in a subset (~40%) of ovarian carcinomas.
Higher expression of KLK5 was found to be significantly more
frequent in patients with advanced stage diseases and in poorly
differentiated tumours (grade III). The present study does not
provide any evidence for a direct cause and effect relationship
between KLK5 expression and tumour progression. However, it is
reasonable to hypothesize a potential role of KLK5 in promoting
tumour invasiveness and metastasis. As mentioned earlier, KLK5
structurally resembles EMSP-1 (54% amino acid sequence iden-
tity, 68% similarity), which degrades the enamel matrix protein
and other serine proteinases (Diamandis et al, 2000 ). It would be
interesting to investigate whether KLK5 is similar to EMSP-1 in
terms of its enzymatic activity and substrates.
The observed overexpression of KLK5 mRNA in ovarian carcin-
oma suggests that KLK5 gene transcription may be enhanced in
ovarian tumours. Our laboratory previously demonstrated that
KLK5 is up-regulated by oestrogen (Yousef and Diamandis,
1999). It was recently found that during ovarian carcinogenesis,
oestrogen receptor-a is dramatically increased (Pujol et al, 1998).
Hence, it is conceivable that overexpression of KLK5 occurs as a
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Table 2 Univariate and multivariate analysis of KLK5 with regard to progression-free (PFS) and overall
(OS) survival 
Variable
Progression-free survival Overall survival 
HRa 95% CIb P value HRa 95% CIb P value 
Univariate analysis
KLK5 
Negative 1.00 1.00
Positive 1.68 1.09–2.59 0.018 1.83 1.09–3.06 0.022 
Stage of disease (ordinal) 2.96 2.08–4.21 <0.001 3.52 2.25–5.52 <0.001 
Grading (ordinal) 2.26 1.60–3.21 <0.001  2.55 1.59–4.07 <0.001 
Residual tumour (ordinal) 1.25 1.17–1.32 <0.001 1.31 1.21–1.41 <0.001 
Histologic typec 1.42 0.92–2.19 0.11 1.33 0.79–2.24 0.27 
Age 1.01 0.99–1.03 0.18 1.01 0.99–1.03 0.21 
Multivariate analysis
KLK5 
Negative 1.00 1.00
Positive 1.27 0.78–2.06 0.32 1.45 0.82–2.54 0.19 
Stage of disease (ordinal) 1.87 1.28–2.75 0.001 2.03 1.24–3.31 0.004 
Grading (ordinal) 1.45 0.97–2.18 0.061 1.55 0.90–2.69 0.11 
Residual tumour (ordinal) 1.13 1.05–1.22 0.001 1.21 1.10–1.32 <0.001 
Histologic typec 1.06 0.67–1.68 0.78 0.83 0.48–1.43 0.51 
Age 1.02 0.99–1.04 0.12 1.02 0.99–1.05 0.095 
aHazard ratio (HR) estimated from Cox proportional hazard regression model; bConfidence interval of the
estimated HR; cEndometrioid, undifferentiated and others vs. serous. KLK5 expression in ovarian carcinoma 647
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Table 3 Associations between KLK5 and progression-free (PFS) and overall (OS) survival stratified
by the tumour grade 
Variable
Progression-free survival Overall survival 
HRa 95% CIb P value HRa 95% CIb P value 
Tumour grade I–II 
Univariate analysis
KLK5 negative 1.00 1.00
KLK5 positive 3.59 1.43–9.01 0.006 3.07  0.97–9.71 0.055 
Multivariate analysisc
KLK5 negative 1.00 1.00
KLK5 positive 3.89 1.26–12.02 0.018 3.26 0.74–14.23 0.12 
Tumour grade III 
Univariate analysis
KLK5 negative 1.00 1.00
KLK5 positive 1.07 0.65–1.75 0.78 1.37  0.76–2.44 0.29 
Multivariate analysisc
KLK5 negative 1.00 1.00
KLK5 positive 1.19 0.67–2.11 0.56 1.51  0.76–2.96 0.23 
aHazard ratio (HR) estimated from Cox proportional hazard regression model; bConfidence interval of
the estimated HR; cMultivariate models were adjusted for stage of disease, residual tumour, histologic
type and age. 
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Figure 2 Kaplan–Meier survival analysis of progression free (top) and
overall survival (bottom) in patients with ovarian cancer who were either
KLK5 positive or KLK5 negative. n: number of patients 
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Figure 3 Kaplan–Meier survival analysis of progression free (top) and
overall survival (bottom) in patients with grade I/II tumour who were either
KLK5 positive or KLK5 negative. n: number of patients 648 H Kim et al 
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Table 4 Associations between KLK5 and progression-free (PFS) and overall (OS) stratified by the
debulking success 
Variable Progression-free survival Overall survival 
HRa 95% CIb P value HRa 95% CIb P value 
Optimal debulking 
Univariate analysis
KLK5 negative 1.00 1.00
KLK5 positive 3.08 1.33–7.13 0.008 1.83  0.59–5.70 0.29 
Multivariate analysisc
KLK5 negative 1.00 1.00
KLK5 positive 2.86 1.02–8.06 0.049 1.14  0.33–3.97 0.83 
Suboptimal debulking 
Univariate analysis
KLK5 negative 1.00 1.00
KLK5 positive 1.23 0.74–2.03 0.42 1.95  1.09–3.47 0.023 
Multivariate analysisc
KLK5 negative 1.00 1.00
KLK5 positive 1.27 0.68–2.36 0.44 2.56  1.31–5.03 0.006 
aHazard ratio (HR) estimated from Cox proportional hazard regression model; bConfidence interval of
the estimated HR; cMultivariate models were adjusted for stage of disease, tumour grade, histologic
type and age. 
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Figure 4 Kaplan–Meier survival analysis of progression free (top) and
overall survival (bottom) in patients with grade III tumour who were either
KLK5 positive or KLK5 negative. n: number of patients 
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Figure 5 Kaplan–Meier survival analysis of progression free (top) and
overall survival (bottom) in patients with optimal debulking who were either
KLK5 positive or KLK5 negative. n: number of patients result of an increased number of hormone-receptor complexes,
which would, in turn, up-regulate KLK5. Further investigation is
warranted to address this question. 
Loss of differentiation in higher-grade tumours occurs as a
result of altered cellular signalling pathways which govern cell
growth and differentiation (reviewed in Hanahan and Weinberg,
2000). In essence, changes of cell signalling in cancer cells occur
in favour of growth while circumventing terminal differentiation.
As shown in Table 1, KLK5 expression increases most noticeably
between grade I and grade II tumours, raising the question of 
a potential link between KLK5 and cellular differentiation or
signalling pathways during tumour progression. 
Our findings demonstrate that the KLK5 expression correlates
with increased risks of relapse and death in univariate but not
multivariate analysis (Table 2). This implies that KLK5 positivity
is not an independent prognostic factor, but rather, a parameter
associated with late-stage, and high-grade ovarian tumours. In
early grade cancer, KLK5 expression does have independent
prognostic value for a subgroup of patients (40 patients) but only
for disease-free survival (Table 3). Among optimally debulked
patients, KLK5 expression independently predicts disease-free
survival while in suboptimally debulked patients, KLK5 expres-
sion independently predicts overall survival. Our lack of knowl-
edge of KLK5 function and regulation in normal and cancerous
tissues does not allow us to formulate reasonable hypotheses to
explain these phenomenological observations. More studies with a
larger group of patients will be necessary to substantiate these
data. 
In conclusion, the present study suggests that KLK5 could be a
useful, independent prognostic indicator in patients with grade I/II
ovarian tumours. In these patients, assessment of KLK5 expres-
sion could assist physicians to determine those who are at higher
risk for relapse. While the presented data pertain to KLK5 mRNA
expression, KLK5 protein is likely secreted (Yousef and
Diamandis, 1999). Thus, the current findings provide evidence to
support a potential utility of this gene and the encoded protein in
developing a diagnostic test for ovarian cancer patients. 
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